FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 143 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 Study in India Could Make Immunotherapy More Affordable Worldwide November 22, 2022 Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... April 22, 2021 Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... May 24, 2023 Load more HOT NEWS Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations... Bringing a Piece of Home to the Hospital
